Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bioterrorism -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (815)	2/8/2005 2:39:43 PM
From: scaram(o)uche	Respond to of 891

from today's Myriad filing..... We also have a number of drug candidates in late-stage preclinical development, including a drug candidate for AIDS. MPI-49839, our drug candidate for AIDS, has demonstrated strong anti-HIV activity and has been shown to be effective against many of the drug resistant strains of HIV. MPI-49839 is in late-stage preclinical formulation in preparation for future human clinical testing. Seriously believe that they should also take this "broad spectrum" view, given what they've said about mechanism, and try to access bioterror-related funding.